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ABSTRACT Enterotoxigenic Escherichia coli (ETEC) contributes significantly to the
substantial burden of infectious diarrhea among children living in low- and middle-
income countries. In the absence of a vaccine for ETEC, children succumb to acute
dehydration as well as nondiarrheal sequelae related to these infections, including
malnutrition. The considerable diversity of ETEC genomes has complicated canonical
vaccine development approaches defined by a subset of ETEC pathovar-specific anti-
gens known as colonization factors (CFs). To identify additional conserved immuno-
gens unique to this pathovar, we employed an “open-aperture” approach to capture
all potential conserved ETEC surface antigens, in which we mined the genomic
sequences of 89 ETEC isolates, bioinformatically selected potential surface-exposed
pathovar-specific antigens conserved in more than 40% of the genomes (n=118),
and assembled the representative proteins onto microarrays, complemented with
known or putative colonization factor subunit molecules (n=52) and toxin subunits.
These arrays were then used to interrogate samples from individuals with acute
symptomatic ETEC infections. Surprisingly, in this approach, we found that immune
responses were largely constrained to a small number of antigens, including individ-
ual colonization factor antigens and EtpA, an extracellular adhesin. In a Bangladeshi
cohort of naturally infected children ,2 years of age, both EtpA and a second anti-
gen, EatA, elicited significant serologic responses that were associated with protec-
tion from symptomatic illness. In addition, children infected with ETEC isolates bear-
ing either etpA or eatA genes were significantly more likely to develop symptomatic
disease. These studies support a role for antigens not presently targeted by vaccines
(noncanonical) in virulence and the development of adaptive immune responses
during ETEC infections. These findings may inform vaccine design efforts to comple-
ment existing approaches.
KEYWORDS diarrhea, enteric pathogens, pathogenesis, surface antigens, vaccines
Enterotoxigenic Escherichia coli (ETEC) is one of the most common causes of child-hood diarrhea, accounting for hundreds of millions of cases annually (1). This high
burden of disease is associated with a substantial risk of increased childhood morbidity
and mortality (2–4). Repeated diarrheal infections, including those caused by ETEC,
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lead to the development of growth stunting and environmental enteropathy, which
are lifelong consequences of these enteric infections (5). Therefore, preventative
efforts, including vaccination, could have a tremendous impact on global health (6).
Despite the lack of a licensed ETEC vaccine, two important lines of evidence suggest
that ETEC vaccine development is feasible. First, controlled human infection models
(CHIMs) demonstrate that protective immunity develops following ETEC challenge (7,
8). In addition, the frequency of symptomatic infections in young children living in
regions of endemicity wanes substantially with age (9, 10), suggesting that natural
infections afford subsequent protection.
ETEC biology, and the extraordinary genetic plasticity of E. coli, has complicated the
development of a broadly protective vaccine. Canonical approaches have focused
primarily on surface features known as colonization factors (CFs) or Coli Surface (CS)
antigens. However, the structural and antigenic diversity of these targets has proved
challenging (11). Although toxoids that can elicit neutralizing antibodies against the
heat-labile toxin (LT) (12) and heat-stable toxin (ST) (13) that define the ETEC pathovar
are currently under development (14, 15), it is not yet clear whether these alone will
afford sufficient, long-lasting protection.
While the ETEC pathovar exhibits high genetic diversity, the recent availability
of multiple genomic sequences from globally diverse ETEC strains affords the ability
to apply reverse-vaccinology approaches to the identification of conserved, surface-
expressed antigens (16, 17). In addition, microarray-based profiling of immune re-
sponses in human volunteers to ETEC challenge has recently highlighted noncanoni-
cal antigens (those not targeted in ETEC vaccines to date) that are recognized during
controlled experimental infection (7, 18).
The application of these approaches to antigen discovery has reinforced the impor-
tance of several surface-expressed molecules common to the ETEC pathovar that are
not currently targeted in classical vaccine approaches (19). These include two novel
secreted molecules, the EtpA adhesin (20) and the EatA autotransporter (21), both orig-
inally identified in H10407, an ETEC strain isolated from a case of severe cholera-like di-
arrhea in Bangladesh. Recent work demonstrates that both antigens are globally dis-
tributed in the ETEC pathovar and are more highly conserved than the most common
CFs (19, 22). Moreover, they are protective in murine models of infection (23–26) and
immunogenic in human challenge trials (7, 18), suggesting that these molecules could
provide additional antigenic targets for vaccine development. While much is known
about EatA and EtpA under experimental conditions, less is known about their respec-
tive roles in natural infections. The present studies were designed to explore the roles
of these and other potential noncanonical antigens in shaping the adaptive immune
response to ETEC infection and to examine their contribution to virulence.
RESULTS
Antibodies following natural infection recognize a finite repertoire of ETEC
proteins. Both human experimental models (7) as well as natural infections (10) dem-
onstrate that prior infection with ETEC affords substantial protection against sympto-
matic disease. Elucidation of the nature of protective adaptive immune responses to
these mucosal pathogens can therefore inform vaccine development. While the major-
ity of previous ETEC vaccinology efforts have centered on a canonical approach
focused on colonization factor (CF) antigens, the present studies were designed to
broadly profile antigenic responses to CFs as well as noncanonical antigens that have
not been specifically targeted in vaccines to date. To assess the breadth of immune
responses to ETEC during acute natural infection, we designed protein microarrays
containing all proteins bioinformatically predicted (see Fig. S1 in the supplemental ma-
terial) to be both surface-expressed proteins and conserved in more than 40% of the
ETEC pathovar strains. These included EtpA and EatA, secreted antigens expressed by a
majority of ETEC strains in a global collection of isolates (19). Although no single CF
antigen was conserved in at least 40% of ETEC strains, each of the known CF protein
subunits was also included on the arrays.
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Despite the inclusion of multiple candidate surface molecules on the array predicted
to be conserved among strains in Bangladesh from our in silico analysis, immune
responses following infection were largely constrained to a small group of antigens,
including EtpA and EatA (Fig. 1A), LT (Fig. S2), and select colonization factor subunits
(Fig. S3). The latter included CssB, one of two components of the CS6 polymer (27), a
predominant immunogenic antigen among strains circulating in Bangladesh (28).
Compared to control specimens obtained outside the area where ETEC is endemic, both
EatA and EtpA exhibited high levels of reactivity. Notably, for patients infected with
EtpA-expressing strains, EtpA responses were significantly higher at day 30 following
infection than those observed immediately following admission, whereas the converse
was true in patients admitted with EtpA-negative strains (Fig. 1B).
In an open-aperture assessment of antibody lymphocyte supernatant (ALS) speci-
mens (29, 30) obtained from adults hospitalized at the International Centre for
Diarrheal Disease Research, Bangladesh (icddr,b), Hospital in Dhaka, Bangladesh, or
from patients recruited at the Mirpur field site with acute symptomatic diarrheal illness,
FIG 1 Serologic response to noncanonical antigens following natural infection. (A) Heat map of log2-
transformed Z-score data indicating ETEC protein microarray responses from days 2 and 30 following
presentation to the icddr,b to four noncanonical antigens, EtpA, YghJ, the passenger domain of EatA, and
EaeH, and the B subunit of ETEC heat-labile toxin (LT-B). (B) Kinetic ELISA responses to EtpA and EatA following
infection. Data are segregated by the presence or absence of the respective antigen in the strain recovered at
presentation. Negative-control samples from St. Louis Children’s Hospital (slch) are shown as open circles. *,
P , 0.05 by a Wilcoxon matched-pairs signed-rank test.
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we again noted that immune responses following infection were largely constrained to
a relatively small group of antigens, including CS6, EtpA, and EatA (Data Set S2). When
parsing antigen profiles of the infecting strain, we found that those individuals infected
with EtpA-expressing ETEC exhibited significant increases in both ALS IgA (P=0.005)
and IgG (P=0.02) responses in the week following infection relative to those infected
with EtpA-negative strains (Fig. 2). As anticipated, we also observed significant
increases in ALS immunoreactivity to the CssB subunit of CS6 that correlated with the
production of CS6 by the infecting strain (Fig. S3).
EatA and EtpA are immunogenic in young children. Data from recent controlled
human infection model studies (7, 18) as well as earlier data from patients with natural
ETEC infections (22) indicate that adults develop robust immune responses to nonca-
nonical antigens, including EtpA and EatA. However, in areas of endemicity, young chil-
dren are the population most severely impacted by ETEC, with incidence declining af-
ter 24months of age, presumably as protection develops after infection. Therefore, we
examined sera from a cohort of Bangladeshi children monitored from birth through
2 years of age (10) to profile the development of antibody responses to EatA and EtpA
over time (Fig. 3). During the first month of life, the majority of children were observed
to have elevated IgG responses to both EatA and EtpA, presumably reflecting the pas-
sive transfer of maternal antibodies (31). As anticipated, responses to both antigens
decreased by 3 months of age, while mean responses to each antigen increased signifi-
cantly through 24months of age, likely reflecting early childhood infections with
strains expressing EtpA and EatA.
FIG 2 ALS responses to EtpA or EatA. Shown are microarray data for IgA (top) and IgG responses to
EtpA (left) and the passenger domain of EatA (EatAp) (right) on days 2 and 7 following hospitalization.
Data in each graph are segregated according to antigen expression in the infecting strain (negative or
positive). P values reflect Kruskal-Wallis values, with post hoc analysis using Dunn’s test adjusted for
multiple comparisons for between-group analysis.
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Anti-EtpA or -EatA responses relative to symptomatic diarrhea. Immunological
correlates of protection against ETEC are currently unknown (32). The majority of clini-
cal studies to date have examined the impact of prior infection with strains producing
particular colonization factors and/or LT (9) as well as antibody acquisition on the sub-
sequent risk of infection with similar strains (33, 34). We hypothesized that because
EtpA and EatA are relatively common antigens in the ETEC pathovar (19), higher anti-
body responses to these antigens may be associated with subsequent protection
against symptomatic infection. After excluding antibody responses at 1 month of age,
we examined the IgG antibody responses to EtpA and EatA preceding the detection of
ETEC in either symptomatic or asymptomatic children between 4 and 24 months of
age. Interestingly, we observed elevated responses to both antigens prior to the detec-
tion of ETEC in asymptomatic children relative to symptomatic cases (Fig. 4; Fig. S5),
perhaps reflecting the overall mitigating impact of prior exposure on the development
of diarrheal illness.
Association of eatA and etpA with virulence. Although both EatA, a mucin-
degrading serine protease, and the EtpA blood group A lectin are secreted by a diverse
population of ETEC strains (19) and contribute to virulence phenotypes in vitro as well
FIG 3 Anti-EtpA or anti-EatA IgG responses increase with age. Shown are representative kinetic ELISA
data for serum IgG samples obtained from children aged 1 to 24months enrolled in a birth cohort
study. Scatterplots of anti-EtpA and anti-EatA IgG plotted against data for children aged 3 to 24 months
with regression lines from linear repeated-measures models overlaid (dotted lines) demonstrate significant
increases over time in the responses to the passenger domain of EatA (EatAp) (top) and EtpA (bottom).
See Fig. S4 in the supplemental material for additional plots.
Noncanonical Antigens and ETEC Virulence Infection and Immunity
May 2021 Volume 89 Issue 5 e00041-21 iai.asm.org 5
 on M










as in small-animal models of ETEC infection (23, 26, 35, 36), the role played by these
antigens in human infections has yet to be explored in detail. To explore the associa-
tion of eatA and etpA with symptomatic ETEC infection, we examined isolates collected
in a birth cohort study in which stool specimens were collected at monthly intervals
from asymptomatic children (asymptomatic colonization) or during surveillance for di-
arrhea (symptomatic infection) (10). Notably, the presence of etpA or eatA significantly
increased the odds of having symptomatic diarrhea (unadjusted odds ratios of 2.1 and
3.1, respectively) (Table 1). Similarly, after adjusting for age, we observed significant
associations between the presence of either EtpA (adjusted odds ratio of 1.98;
P=0.007) or EatA (adjusted odds ratio of 2.91; P, 0.001) and the development of diar-
rheal disease.
FIG 4 Serum IgG responses preceding asymptomatic ETEC colonization and diarrhea. Shown are peak
serum IgG responses for EtpA (left) or the EatA passenger domain (right) preceding either
asymptomatic colonization or diarrheal illness with ETEC. Data shown are log10-transformed IgG
antibody responses determined by a kinetic ELISA. Bars represent mean values. P values reflect
Student’s t testing.




No. of samples (%)
with antigen status Unadjusted odds ratio Age-adjusted odds ratio
Negative Positive Odds ratio (95% CI) P value Odds ratio (95% CI) P value
EtpA
All 2 110 (40.6) 161 (59.4) 2.10 (1.28, 3.45) 0.003 1.98 (1.21, 3.29) 0.007
1 27 (24.5) 83 (75.5)
ST or ST/LT 2 55 (34.4) 105 (65.6) 1.57 (0.89, 2.77) 0.116 1.51 (0.86, 2.68) 0.156
1 24 (25) 72 (75)
LT only 2 55 (49.5) 56 (50.5) 3.60 (0.95, 13.61) 0.047 2.59 (0.78, 10.79) 0.144
1 3 (21.4) 11 (78.6)
EatA
All 2 152 (56.1) 119 (43.9) 3.11 (1.93, 5.01) ,0.001 2.91 (1.81, 4.75) ,0.001
1 32 (29.1) 78 (70.9)
ST or ST/LT 2 67 (41.9) 93 (58.1) 2.05 (1.18, 3.56) 0.011 1.91 (1.1, 3.38) 0.024
1 25 (26) 71 (74)
LT only 2 85 (76.6) 26 (23.4) 3.27 (1.05, 10.18) 0.051 2.36 (0.74, 7.46) 0.142
1 7 (50) 7 (50)
aP values for unadjusted odds ratios were obtained from simple chi-square or Fisher’s exact tests, and P values for age-adjusted odds ratios were obtained from logistic
regressions that included age as a covariate.
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The eatA gene (21) and the etpBAC locus (20), encoding the two-partner secretion
system responsible for EtpA secretion, were originally identified on the p948 plasmid
of ETEC strain H10407, which also harbors the gene for STh (37), and our previous stud-
ies suggested that both loci are more commonly associated with ST-producing strains
(19). Importantly, large epidemiological studies have demonstrated an association
between ST- or ST/LT-producing ETEC and more severe disease than with LT-only-pro-
ducing ETEC (38, 39). Similarly, we again found an association between ST-producing
ETEC and symptomatic diarrhea, where 59.0% of colonizing ETEC isolates encode STh
or STp (estH or estP positive), compared to 87.3% of diarrhea-associated isolates
(adjusted odds ratio, 4.66 [95% confidence interval {CI}, 2.62, 8.85]; P, 0.001]). We
therefore asked whether the eatA or etpA associations with virulence were independ-
ent of ST. The presence of either gene was associated with a higher risk of diarrheal ill-
ness independent of ST, although only the presence of eatA was significantly associ-
ated with illness adjusted for age. Collectively, however, these data suggest that these
more recently discovered noncanonical antigens, now often referred to as “accessory”
virulence factors, appear to be more frequently identified in ETEC strains causing acute
diarrheal illness.
DISCUSSION
ETEC strains were initially discovered in patients presenting with severe diarrheal ill-
ness that mimicked clinical cholera (40–42). Following seminal discoveries of the heat-
labile (LT) and heat-stable (ST) toxins that define ETEC and the initial characterization
of plasmid-encoded colonization factor (CF) antigens, a canonical approach to vaccine
development focused on LT and CFs emerged. However, subsequent studies have
revealed that the molecular pathogenesis of ETEC likely involves a number of other
plasmid-encoded as well as chromosomally-encoded features that may potentially
expand the repertoire of target “noncanonical” antigens for use in ETEC vaccine
development.
The intent of the protein microarray studies presented here was to facilitate the
identification of novel, surface-expressed, immunogenic proteins conserved within the
ETEC pathovar for investigation as feasible antigenic targets in future iterations of ETEC
vaccines. To encompass as many relevant antigens as possible (“open aperture”), we
selected any predicted surface-expressed protein encoded by more than 40% of ETEC
strains but absent in commensal E. coli strains. Notably, because all of the known colo-
nization factors, the principal targets for ETEC vaccines to date, failed to meet this mini-
mal conservation cutoff, they were used to complement the conserved features on the
array. In general, this expanded open-aperture assessment of immune responses to
natural ETEC infections appears to reaffirm previous observations in human volunteer
studies (7) demonstrating that there are relatively few conserved immunogenic targets
in the potential repertoire of ETEC surface molecules.
Among the more recently discovered surface immunoreactive (7, 18, 43) antigens
conserved within the ETEC pathovar (18, 19) are two high-molecular-weight secreted
proteins, EtpA and EatA. Our understanding of the contribution of these antigens to
ETEC virulence continues to evolve. Recent studies have revealed that the secreted
110-kDa passenger domain of the EatA autotransporter protein functions as a mucin-
degrading enzyme capable of dissolving the MUC2 matrix that covers the surface of
enterocytes, the target for ETEC binding and toxin delivery (23). EtpA, secreted by a
two-partner secretion mechanism that requires both the EtpB outer membrane pore
and EtpC, a glycosyltransferase (20), functions as an adhesin by bridging the bacteria
(36) and GalNAc-containing host cell glycans present on enterocytes (44). However, de-
spite an emerging understanding of the molecular function of these molecules, very
little is known about their actual contribution to disease in human hosts.
The present studies extend previous observations to a cohort of naturally infected
children in Bangladesh (10) and suggest that these noncanonical antigens play critical
roles in determining the outcome of ETEC infections. The finding that genes encoding
Noncanonical Antigens and ETEC Virulence Infection and Immunity
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these antigens are significantly associated with the development of symptomatic
infection may have important implications for the interpretation of large-scale epide-
miological studies that have employed a population-attributable fraction methodology
in which ETEC strains detected in cases of diarrheal illness are compared to those of
asymptomatically colonized controls (4). The present studies seem to suggest that
additional characterization of ETEC beyond the pathovar-defining heat-labile or heat-
stable toxins could be required to accurately assess the contribution of ETEC to the
global burden of diarrheal disease.
As with a number of important enteric pathogens, true mechanistic correlates of
immune responses directly responsible for protection (45) against ETEC remain unde-
fined (32, 46). Although we observed high IgG serum antibody responses to both EtpA
and EatA in children who were simply colonized with ETEC compared to those with di-
arrhea, suggesting that these antigens could afford some protection against sympto-
matic illness, these findings need to be interpreted cautiously. Both EtpA and EatA are
relatively common antigens among strains circulating in Bangladesh; therefore, the
identification of antibodies could simply reflect prior infection that mitigates infection
through responses to other antigens.
Altogether, however, the findings reported here suggest that antigens that have
not been part of traditional approaches to vaccine development may play important
roles in virulence and in acquired immunity to ETEC. Further studies will clearly be
needed to examine the efficacy of these more recently discovered antigens as protec-
tive immunogens and their role in complementing colonization factors and heat-labile
toxin that have played a fundamental role in canonical approaches to vaccine
development.
MATERIALS ANDMETHODS
Clinical samples used in this study. Specimens used in these studies were obtained from archived
studies on an ETEC birth cohort carried out in Mirpur in Dhaka city (10) as well as other studies (28) at
the International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b). Frozen ETEC isolates
were retrieved from storage (280°C), and duplicate vials were shipped to Washington University for sub-
sequent antigen detection.
Microbial genome analysis and bioinformatic antigen selection. Genomes from 89 clinical ETEC
isolates previously collected at icddr,b were used to identify conserved surface proteins. Sequence
data for all 89 clinical isolates examined in this study are available in GenBank (47). Paired-end
Illumina sequence data for each isolate were generated de novo, and contigs were binned using a
previously described protocol (47). The ETEC genomes were compared using large-scale BLAST score
ratio (LS-BSR) analysis as previously described (48–50). The predicted protein-encoding genes of
each genome that had $90% nucleotide identity to each other were assigned to gene clusters using
uclust (51). Representative sequences of each gene cluster were then compared to each genome
using TBLASTN (52) with composition-based adjustment turned off, and the TBLASTN scores were
used to generate a BSR value indicating the detection of each gene cluster in each of the genomes
analyzed. The BSR value was determined by dividing the score of a gene compared to a genome by
the score of the gene compared to its own sequence. The predicted protein function of each gene
cluster was determined using an ergatis-based (53) in-house annotation pipeline (54). A total of
13,835 nonredundant putative genes (referred to here as “centroids”) were extracted from the 89
genomes.
All 13,835 centroids in this study were subjected to a reverse-vaccinology pipeline (illustrated in
Fig. S1 in the supplemental material) (Institute for Genome Sciences, MD, USA) to identify molecules
conserved in the ETEC pathovar that contained features that suggested that they were surface
exposed. Briefly, subtractive analysis was first conducted by filtering centroids (BLASTx and BLASTn)
against the genome contents of six E. coli commensal and laboratory strains, yielding 6,444 ETEC path-
ovar-specific centroids. These data were further refined by selecting centroids with a BSR (55) of $0.8
and present in at least 40% of the clinical isolates, yielding 316 conserved, virulence-linked genetic
features for further analysis. BLASTx was next used to assign a putative function to these virulence-
linked centroids. This analysis was coupled with results from pSORTv3.0 (56), SubLoc (57), and CELLO
(58) to predict subcellular localization, altogether resulting in down-selection to 118 potential surface-
expressed molecules. These features were complemented with all known and putative colonization
factor subunits (n= 52), toxin subunits, and subdomains of novel antigens for inclusion on the micro-
arrays (Data Set S1).
Microarray production. Antigen-encoding regions selected for the microarrays were amplified by
PCR using primers listed in Data Set S1 and constructed as previously described (7, 18, 59). Recombinant
versions of select antigens, including EtpA, EatA, LT-A, LT-B, YghJ, STh, and EaeH, were also included on
the arrays.
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Microarray processing. Microarrays were shipped to icddr,b, where they were rehydrated for 10
min with 100ml array blocking buffer (catalog number 10485356; GVS). The E. coli lysate was reconsti-
tuted in a final volume of 20% in array blocking buffer. Archived antibody lymphocyte supernatant (ALS)
samples prepared from the blood of ETEC patients as previously described (29) were diluted 1:2.5 in the
resuspended lysate, followed by loading onto the microarrays, and incubated in the dark for 2 h at 25°C
on a rotating platform. Microarrays were then washed three times with TBS-T (0.05% Tween in Tris-buf-
fered saline [TBS] [pH 7.5]), followed by incubation for 5 min in TBS-T at 25°C. This process was repeated
once with TBS, followed by a final wash in distilled water. Slides were dried by centrifugation (10 min at
500 g) and then stored in desiccated boxes prior to shipping to the Felgner Laboratory, University of
California, Irvine, for processing with anti-human IgA and anti-human IgG.
Noncanonical antigen ELISA. Plates (384-well plates, product number 3540; Corning) were coated
with a recombinant EatA passenger domain (rEatp) (10mg/ml in carbonate buffer [15mM Na2CO3,
35mM NaHCO3, 0.2 g/liter NaN3 {pH 9.6}]) or recombinant EtpA (rEtpA) (1mg/ml in carbonate buffer)
and shipped to icddr,b, being maintained at 4°C prior to use. The enzyme-linked immunosorbent
assay (ELISA) plates were manually washed three times with PBS-T (phosphate-buffered saline [PBS]
with 0.05% Tween), including brief centrifugation for 30 s at 200 g on a tabletop centrifuge between
washes. Plates were rehydrated with 1% bovine serum albumin (BSA) in PBS-T overnight at 4°C. The
following day, serum or plasma samples and plates were warmed to ambient temperature (;25°C),
and serum was diluted 1:200 in PBS-T with 1% BSA and briefly vortexed. Ten microliters of diluted se-
rum was added to the plates, centrifuged as described above, sealed, and incubated at 37°C for 1 h.
After incubation, plates were washed 3 times with PBS-T as described above. Ten microliters of horse-
radish peroxidase (HRP)-conjugated anti-human IgG (catalog number 309-035-006; Jackson
ImmunoResearch Laboratories, West Grove, PA) was diluted 1:2,000 in 1% BSA in PBS-T, followed by
incubation and washing as described above. ELISA plates were read using 10ml of 3,39,5,59-tetrame-
thylbenzidine (TMB) substrate (catalog number 50-76-00; Seracare, Milford, MA). A kinetic ELISA (60)
was used to determine relative antibody concentrations (Eon, Gen5 Take3, v.2.00.18; BioTek). Each
plate was analyzed separately, and Vmax titers were normalized to the mean negative-control value of
the plate.
Strain characterization by PCR and immunoblotting. Frozen glycerol stocks of ETEC strains main-
tained at 280°C were used to inoculate lysogeny broth (LB) for overnight growth at 37°C at 250 rpm.
One microliter of the culture grown overnight was diluted in 100ml of PBS, of which 1ml was used as
the DNA template in initial PCR screening with primers listed in Table S1. The thermocycler conditions
for eatA and etpA were a denaturation step for 5 min at 95°C with 30 amplification cycles utilizing 95°C
for 30 s, 52°C for 30 s, and 72°C for 2 min. The toxin multiplex assays (genes eltB, estH, and estP) were
conducted as follows: 5 min at 95°C with 32 cycles of amplification using 94°C for 15 s, 55°C for 15 s, and,
finally, 72°C for 30 s. Amplicons were visualized as described above using a 0.8% agarose gel with ethi-
dium bromide. The H10407 strain (eatA, etpA, estH, estP, and eltB positive) was used as a positive control
for the assays.
To adjudicate discordant results, PCR was performed using genomic DNA (gDNA) extraction with the
Invitrogen PureLink Quick plasmid miniprep kit (catalog number K210010; Thermo Fisher, Waltham,
MA). If toxin multiplex PCRs were negative, isolates were deemed to have lost their original plasmid dur-
ing storage, transportation, or culture passage and subsequently excluded from the analysis.
Immunoblotting for EatA and EtpA was performed on tricarboxylic acid (TCA)-precipitated culture
supernatants, as previously described (19), using affinity-purified polyclonal rabbit antibodies against
the passenger domain of EatA (21) or EtpA (20) (dilutions of 1:1,000 and 1:5,000, respectively). Primary
antibodies were detected using HRP-conjugated anti-rabbit IgG secondary antibody (1:5,000 dilution)
(catalog number A16110; Invitrogen) for 1 h at room temperature. HRP was detected with the ECL
Western blotting substrate (catalog number ABIN412579; Bio-Rad).
Statistical analysis. Categorical outcomes were analyzed using chi-square tests, Fisher’s exact tests,
or age-adjusted logistic regression analyses as appropriate. Serum data were analyzed using a linear
repeated-measures model with a compound symmetry covariance structure. P values of ,0.05 were
considered significant. Analyses were conducted using SAS version 9.4 (SAS Institute Inc., Cary, NC, USA),
SPSS v.24 (IBM, Armonk, NY, USA), or GraphPad Prism v9.0.0.
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